Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEFOSPROST
2024-513465-39-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Acute Prostatitis comparing fosfomycin oral monotherapy, cefixime oral monotherapy and ciprofloxacin oral monotherapy (3 arms). Primary endpoint: Clinical cure at 6–10 days post-end of treatment. Planned start Aug 2024; status: authorised.
02
Drugs
fosfomycincefiximeciprofloxacin
03
Conditions
Acute Prostatitis
Beyond the preview
Go deeper on 2024-513465-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513465-39-00.